(Q38915884)

7 September 2017

Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity (English)

1 reference

7 September 2017

1 reference

1 reference

7

Li Li

1 reference

7 September 2017

Yang Yan

1

1 reference

7 September 2017

Songyan Li

2

1 reference

7 September 2017

Tingting Jia

3

1 reference

7 September 2017

Xiaohui Du

4

1 reference

7 September 2017

Yingxin Xu

5

1 reference

7 September 2017

Yunshan Zhao

6

1 reference

7 September 2017

Kai Liang

8

1 reference

7 September 2017

Wentao Liang

9

1 reference

7 September 2017

Huiwei Sun

10

1 reference

7 September 2017

Rong Li

11

1 reference

7 September 2017

28 January 2015

1 reference

7 September 2017

1 reference

7 September 2017

36

1 reference

7 September 2017

6

1 reference

7 September 2017

4535-4543

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-3098-7

7 September 2017

0 references

cites work

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Oncolytic viruses: a novel form of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Evolution of oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Interleukin 15 as a promising candidate for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Interleukin-15 in gene therapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

IL-15 has innate anti-tumor activity independent of NK and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Manipulating immune cells for adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Adoptive T cell therapy for cancer in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Armed replicating adenoviruses for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3098-7

In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model

21 January 2018

1 reference

12 December 2020

Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel

1 reference

12 December 2020

An engineered three-dimensional gastric tumor culture model for evaluating the antitumor activity of immune cells in vitro

1 reference

12 December 2020

Dynamic tracing of immune cells in an orthotopic gastric carcinoma mouse model using near-infrared fluorescence live imaging

1 reference

12 December 2020

Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.

1 reference

12 December 2020

IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation

1 reference

12 December 2020

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel

1 reference

12 December 2020

10.1007/S13277-015-3098-7

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6fhjukl62vdqbihn7wnapj53za

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1041692410

0 references

Fatcat ID

release_6fhjukl62vdqbihn7wnapj53za

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6fhjukl62vdqbihn7wnapj53za

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/6fhjukl62vdqbihn7wnapj53za

30 July 2022